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Abstract
Background Older people are more susceptible to falls
than younger people. Therefore, as the Dutch population
ages, the total number of falls and costs associated with
them will rise. The use of psychotropic drugs is associated
with an increased risk of falling. To create tailored fall-
prevention programmes, information on the magnitude of
the association between fall incidents and specific psy-
chotropic drugs or drug classes is needed.
Objective The goal of this study was to delineate the
associations between fall incidents and specific psy-
chotropic drugs or drug classes.
Methods In this retrospective cohort study, electronic
patient records, medication records and fall incident reports
were collected for 1415 residents receiving somatic or
psychogeriatric care in 22 nursing homes in the eastern part
of the Netherlands from May 2012 until March 2015.
Using a Cox proportional hazards model, we analysed the
magnitude of the association between psychotropic drugs
and the risk of falling for users and non-users of the psy-
chotropic drugs or drug classes.
Results Antipsychotics (adjusted hazard ratio [aHR] 1.49;
95% confidence interval [CI] 1.12–2.00) and hypnotics and
sedatives (aHR 1.51; 95% CI 1.13–2.02) increase the risk
of falling. There was no difference between the risk
incurred by typical and atypical antipsychotics. However,
within these groups, there were differences between the
most commonly prescribed drugs: haloperidol and queti-
apine were seen to have an association with falls, whereas
pipamperone and risperidone were not.
Conclusions The results suggest falls may be associated
with individual drugs rather than drug classes. Within the
drug classes, clear differences are evident between indi-
vidual drugs. Future fall-prevention programmes should
highlight the differential risks involved with the use of
specific psychotropic drugs, and doctors should take the
fall risk into account when choosing specific drugs.
Key Points
Falls within the nursing home population may be
associated with individual drugs rather than drug
classes.
Differences exist between individual drugs within
drug classes.
1 Introduction
Over 40% of nursing home residents experience a least one
fall each year [1]. A fall is hereby defined as ‘an event that
leads to a person coming to rest on the ground or other
lower level’ [2]. Because the population is aging, and older
people have a higher risk of falling, the number of falls is
likely to increase. Injuries resulting from falls are promi-
nent among the causes of disability in older people [3].
With an expected increase in age-related incidents such as
falls, a rise in associated costs can also be expected [3].
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While falls are often considered accidents, it has been
shown that the incidence of falls significantly differs from a
Poisson distribution, implying that falls are causally con-
nected with external factors [5].
Factors that influence the risk of falling (besides age)
include state of health [4, 5] and drug use. The former is
difficult to influence, whereas the latter can be influenced
by changing medication prescriptions. For instance,
polypharmacy, defined as the simultaneous use of more
than five drugs, increases the risk of adverse events such as
falls [4, 6, 7]. In the Netherlands, people aged[75 years
use five times as many prescription drugs as the average
citizen, and they use these drugs predominantly chronically
[8].
Some drugs are more harmful than others when included
in polypharmacy. The Screening Tool of Older Person’s
Prescriptions (STOPP) lists the potentially inappropriate
medications (PIMs) for older people [9], including several
classes of psychotropic drugs. In several studies, these
drugs were the most prevalent PIMs.
An association between the increased risk of falling in
older people and the use of psychotropic drugs was pre-
viously reported in the meta-analysis of three systematic
reviews of the literature between 1966 and 2007 [10, 11].
The most recent review [12] provided the most extensive
overview. The three systematic reviews found that all
psychotropic drug classes were associated with an
increased risk of falling. The pooled odds ratios (ORs)
ranged between 1.37 and 1.71 for antipsychotics, between
1.31 and 1.54 for sedatives and hypnotics and between 1.59
and 1.72 for antidepressants. It should be noted that these
studies present the drugs by classes, whereas the specific
drugs within these classes may have different chemical
properties and may thus have different effects on the risk of
falling.
Literature on the contribution of specific psychotropic
drugs to fall frequency in older people is inconsistent. Only
a few studies have investigated the fall risk of specific
drugs. Two studies showed that the use of the sedative drug
zolpidem is associated with an increased risk of falling,
with an OR of between 2.51 and 4.37 [13, 14], which are
both higher than the pooled estimates for the whole drug
class of sedatives. An increased fall risk for individual
drugs has been found for haloperidol (OR 6.09) [15]. Some
studies did not show an increased risk of falling for the
atypical antipsychotic drugs quetiapine and risperidone
[16], and no significant fall risk was found for temazepam
[17]. Given the lack of evidence of fall risks for specific
drugs, treatment guidelines often report only those risks
associated with the classes of psychotropic drugs and not
possible differences between the drugs within these classes.
Insight into the differences between specific drugs could
raise awareness among physicians and contribute to
decisions regarding the prescription of certain drugs.
Moreover, we expect our exploratory analyses could lead
to more focused follow-up studies with clear hypotheses to
be tested. Therefore, this study examines the association




This was a retrospective cohort study. The cohort was
identified using electronic pharmacy records from May
2012 until March 2015 and included somatic (n = 467)
and psychogeriatric (n = 948) residents and former resi-
dents of long-stay wards in 22 nursing homes in the eastern
part of the Netherlands. Short-stay residents (\60 days)
and physical rehabilitation residents were excluded from
this study.
2.2 Data Collection
Medication records collected from the electronic pre-
scription system included all prescribed drugs, their names
and the start and stop dates as well as the sex and date of
birth of each resident. Drugs prescribed on a pro re nata
basis were excluded from analyses.
Electronic patient records provided patient admission
and, if applicable, discharge dates. The incident report
system provided records of all falls and other types of
incidents. We did not use this system to retrieve informa-
tion on the fall incidents, the patient’s medical condition or
the drug prescribed, because data are entered into this
system as free text and were neither coded nor consistent.
2.3 Data Analysis
All collected data were anonymised by removing names
and birthdates. All prescribed drugs were classified
according to the anatomical therapeutic chemical (ATC)
classification system [33]. Residents’ prescriptions for
identical drugs, and with adjacent stop and start dates, were
combined into one prescription period.
A Cox proportional hazards model was used to inves-
tigate the magnitude of the association between the use of
psychotropic drugs and the risk of falling during the first
60 days after the prescription start date [34]. Outcomes
were calculated with a 95% confidence interval (CI). Crude
hazard ratios (HRs) and adjusted hazard ratios (aHR) were
calculated, with the age, sex, type of department (somatic
or psychogeriatric), polypharmacy, and the use of other
psychotropic drugs as covariates. The use of drugs from
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ATC classes N05A (antipsychotics), N05B (anxiolytics),
N05C (hypnotics and sedatives), N06A (antidepressants)
and N06D (anti-dementia drugs) were entered as separate
covariates. The time to fall (60-day period) was compared
between users and non-users of a specific drug or drug
class. Users were entered into the survival analysis on the
prescription start date. Non-users were entered into the
reference group using a random date from their admission
period. Additionally, possible differences in the effects of
psychotropic drugs on fall incidents were also analysed for
residents receiving psychogeriatric care and residents
receiving somatic care by analysing the two groups sepa-
rately. The model was adjusted for age, sex, polypharmacy,
and the use of other psychotropic drugs as covariates.
All data were processed and analysed with Microsoft
Excel 2010, MySQL Workbench 6.2 and IBM SPSS
Statistics 21.0.
3 Results
A total of 1415 residents were included, with a combined
number of 698,567 patient-days and 3879 fall incidents.
Within this cohort, 795 residents (56.2%) experienced at
least one fall during residence at the nursing home. This
equated to 9.2 falls per 1000 patient-days for this subgroup
and 5.6 falls per 1000 patient-days for the whole cohort.
Table 1 presents the characteristics of the residents and the
number of prescribed psychotropic drugs and fall incidents.
With an average use of 7.9 (±3.7) drugs, polypharmacy
was highly prevalent among the cohort of 1415 residents.
Antipsychotic drugs were prescribed to 42% of all residents
at some point in the study period, and almost half of the
residents (47%) received at least one prescription for a
sedative or hypnotic drug. The most commonly prescribed
psychotropic drugs were temazepam (29%), oxazepam
(20%) and haloperidol (19%). On average, antidepressant
drugs were used for 361 days (standard deviation [SD]
298), which was longer than any other psychotropic drug.
The shortest intake duration was found for hypnotics and
sedatives (average 175 days [SD 228]). Table 2 shows the
magnitude of the association between the use of psy-
chotropic drugs and fall incidents as analysed by the Cox
proportional hazards model.
Looking at the five ATC classes of psychotropic drugs,
an association was seen between fall incidents and the use
of antipsychotics (aHR 1.49; 95% CI 1.12–2.00), hypnotics
and sedatives (aHR 1.51; 95% CI 1.13–2.02), antidepres-
sants (aHR 1.40; 95% CI 1.02–1.85) and anxiolytics (aHR
1.39; 95% CI 1.04–1.86). No association was found for
anti-dementia drugs (aHR 1.32; 95% CI 0.85–2.05).
Typical (aHR 1.40; 95% CI 1.05–1.86) and atypical
antipsychotics (aHR 1.73; 95% CI 1.27–2.36) were both
associated with fall incidents. However, differences were
observed between drugs within these categories. The two
most used typical antipsychotics were haloperidol and
pipamperone; while haloperidol had an aHR of 1.54 (95%
CI 1.13–2.10), no clear association between the use of
pipamperone and fall incidents was found (aHR 1.38; 95%
CI 0.91–2.10). Similar differences within drug categories
were also visible for the two most used atypical antipsy-
chotics, quetiapine (aHR 1.99; 95% CI 1.39–2.85) and
risperidone (aHR 1.31; 95% CI 0.81–2.12). Within hyp-
notics and sedatives, an increased risk of falling was found
for temazepam, zopiclone, zolpidem and melatonin but not
for midazolam: the number of falls (n = 7) in midazolam
users (n = 158) was lower than that for users of other
drugs from this group.
As shown in Table 1, the incidence of falls for residents
in psychogeriatric wards was higher than for those in
somatic wards: 25 versus 5%, respectively, fell more than
four times during their admission. We performed additional
analyses to investigate a possible difference in the magni-
tude of the risk of falling and the use of psychotropic drugs
in somatic and psychogeriatric residents; the results are
shown in Table 3.
Table 3 shows a correlation between the use of
antipsychotics (both typical and atypical) and hypnotics
and sedatives and fall incidents in psychogeriatric resi-
dents. No clear association between the use of any type of
psychotropic drugs and fall incidents was found for somatic
care residents.
4 Discussion
This study reports on the association between falls and
several specific psychotropic drugs and psychotropic drug
classes that are commonly prescribed for nursing home
residents. The risk of falling appeared to increase with the
use of both typical and atypical antipsychotics, hypnotics
and sedatives, antidepressants and anxiolytics, with aHRs
varying between 1.39 and 1.73. A link to falls was found
with the use of the following specific drugs: zolpidem
(aHR 2.35), melatonin (aHR 1.97), quetiapine (aHR 1.99),
temazepam (aHR 1.96), zopiclone (aHR 1.81) and
haloperidol (aHR 1.54). Other specific drugs, such as
pipamperone, risperidone, midazolam, amitriptyline and
citalopram did not show a clear association with falls. Anti-
dementia drugs as a group also did not show any associa-
tion with falls. The increased risks were especially
observed in residents receiving psychogeriatric care, and
falling is also much more prevalent among this group of
residents than among somatic residents.
For the drug classes and three specific drugs (haloperi-
dol, temazepam and zolpidem) that have been investigated
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previously, the results of this study are mostly in line with
other research. We confirmed an increased risk of falling
for residents who received antipsychotics [12]. The most
recent meta-analysis [12] found increased risks for both the
hypnotic and sedative and the antidepressant drug classes,
which we also observed.
In contrast with other studies [17], we found temaze-
pam, the most commonly used hypnotic, to be associated
Table 1 Characteristics of 1415 residents, their falling incidents and their drug prescription data from a total of 1912.6 patient years, observed
between May 2012 and March 2015
Characteristics Total (N = 1415) Psychogeriatric residents
(n = 948 [67%])
Somatic residents
(n = 467 [33%])
Agea 83.5 (± 8.8)
Sex
Female 1000 (71) 687 (72) 313 (67)
Male 415 (29) 261 (28) 154 (33)
Number of drugs used simultaneously 7.9 (3.7) 7.2 (3.4) 9.1 (3.8)
Number of residents who received psychotropic drugs at least once in the study period
Antipsychotics 594 (42) 480 (51) 114 (25)
Typical antipsychotics 409 (29) 339 (36) 70 (15)
Haloperidol 276 (20) 216 (23) 60 (13)
Pipamperone 131 (9) 124 (13) 7 (2)
Atypical antipsychotics 281 (20) 221 (23) 60 (13)
Quetiapine 141 (10) 114 (12) 27 (6)
Risperidone 93 (7) 79 (8) 14 (3)
Anxiolytics 438 (31) 330 (35) 108 (23)
Oxazepam 281 (20) 223 (24) 58 (13)
Lorazepam 150 (11) 117 (12) 33 (7)
Hypnotics and sedatives 664 (47) 443 (47) 221 (47)
Temazepam 416 (29) 262 (28) 154 (33)
Midazolam 158 (11) 116 (12) 42 (9)
Zopiclone 121 (9) 90 (10) 31 (7)
Zolpidem 94 (7) 70 (7) 24 (5)
Melatonin 102 (7) 76 (8) 26 (6)
Antidepressants 502 (36) 339 (36) 163 (35)
Amitriptyline 108 (8) 68 (7) 40 (9)
Citalopram 177 (13) 135 (14) 42 (9)
Anti-dementia drugs 110 (8) 97 (10) 13 (3)
Average number of days used
Antipsychotics 227 ± 255 230 ± 256 211 ± 247
Anxiolytics 216 ± 259 217 ± 258 206 ± 270
Hypnotics and sedatives 175 ± 228 174 ± 227 183 ± 231
Antidepressants 361 ± 298 371 ± 297 303 ± 295
Anti-dementia drugs 340 ± 286 346 ± 286 225 ± 224
Fall characteristics
No falls 618 (44) 314 (33) 304 (66)
One fall 255 (18) 187 (20) 68 (15)
Two falls 131 (9) 98 (10) 33 (7)
Three falls 83 (6) 68 (7) 15 (3)
Four falls 65 (5) 44 (5) 21 (5)
More than four falls 259 (18) 236 (25) 23 (5)
Falls/1000 patient-days 5.6 6.7 2.7
Data are presented as mean ± SD or N (%)
a Average age is calculated using the study inclusion date for those using antipsychotics
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with an increased risk of falling. These different results
might be because other research was conducted in different
health contexts, such as in hospital patients or community-
dwelling subjects, whereas our study was conducted solely
in nursing home residents. Additionally, an adjusted OR of
4.37 (95% CI 3.34–5.76) was previously reported for
zolpidem [14], which suggests a strong association
between this drug and subsequent falling incidents; we
found an increased risk (HR 2.35). Costa-Dias et al. [15]
found an association between haloperidol and falls, with a
reported OR of 6.09; we also found an increased risk, albeit
smaller (aHR 1.54), for haloperidol. The difference might
be due to adjusting for other drugs in variables in the
current study and including nursing home residents instead
of hospitalized patients. Furthermore, we calculated HRs
instead of ORs, which might contribute to these quantita-
tive differences. The advantage of HRs is that they repre-
sent an instantaneous risk rather than a cumulative risk and,
as such, do not depend on the time period investigated.
When interpreting the results, one must consider that, in
some instances, the association between a drug and falling
could be due to a baseline difference in the risk of falling
between users and non-users of the drug rather than the
effect of the drug itself. For example, haloperidol is the
most widely used neuroleptic for the treatment of acute
delirium [18], and delirium itself is associated with a
higher rate of falls. Data on the medical condition of res-
idents in this study were unavailable, so we cannot com-
pletely rule out confounding by indication. Studies that did
take this into account found an increased unadjusted risk
for psychotropic drugs [19, 20] that declined after adjusting
for comorbidities and health status. According to the
STOPP criteria [9], quetiapine is an antipsychotic that can
be prescribed for patients with parkinsonism since it is
regarded as having fewer negative effects on motor control
[21]. Therefore, the results for quetiapine might be con-
founded because physicians may prescribe it for residents
who are already prone to falling. The relatively high aHR
Table 2 Magnitude of the association between commonly prescribed psychotropic drugs, or drug classes, and falls among nursing home
residents
ATC codea Number of users (falls)b Reference group (falls)b HR (95% CI) aHRc (95% CI)
Antipsychotics N05A 594 (110) 821 (89) 1.79 (1.35–2.37) 1.49 (1.12–2.00)
Typical antipsychotics 412 (82) 1003 (126) 1.68 (1.27–2.22) 1.40 (1.05–1.8 6)
Haloperidol N05AD01 275 (57) 1140 (153) 1.64 (1.21–2.22) 1.54 (1.13–2.10)
Pipamperone N05AD05 131 (27) 1284 (184) 1.51 (1.01–2.26) 1.38 (0.91–2.10)
Atypical antipsychotics 281 (60) 1134 (141) 1.82 (1.35–2.46) 1.73 (1.27–2.36)
Quetiapine N05AH04 141 (39) 1274 (167) 2.35 (1.66–3.33) 1.99 (1.39–2.85)
Risperidone N05AX08 93 (19) 1322 (185) 1.49 (0.93–2.39) 1.31 (0.81–2.12)
Anxiolytics N05B 438 (85) 977 (121) 1.64 (1.24–2.17) 1.39 (1.04–1.86)
Oxazepam N05BA04 282 (55) 1133 (153) 1.49 (1.10–2.04) 1.41 (1.03–1.92)
Lorazepam N05BA06 150 (39) 1265 (178) 2.02 (1.43–2.87) 1.53 (1.07–2.20)
Hypnotics and sedatives N05C 664 (111) 751 (82) 1.59 (1.20–2.12) 1.51 (1.13–2.02)
Temazepam N05CD07 416 (90) 999 (127) 1.86 (1.42–2.43) 1.96 (1.49–2.58)
Midazolam N05CD08 158 (7) 1257 (183) 1.47 (0.68–3.16) 1.08 (0.49–2.36)
Zopiclone N05CF01 121 (33) 1294 (181) 2.21 (1.54–3.19) 1.81 (1.24–2.64)
Zolpidem N05CF02 94 (32) 1321 (186) 2.79 (1.92–4.07) 2.35 (1.61–3.44)
Melatonin N05CH01 102 (31) 1313 (184) 2.45 (1.68–3.59) 1.97 (1.33–2.90)
Antidepressants N06A 502 (89) 913 (126) 1.33 (1.01–1.74) 1.40 (1.06–1.85)
Amitriptyline N06AA09 108 (20) 1307 (188) 1.35 (0.85–2.13) 1.49 (0.93–2.38)
Citalopram N06AB04 177 (37) 1238 (182) 1.47 (1.04–2.10) 1.29 (0.89–1.85)
Anti-dementia drugs N06D 110 (23) 1305 (190) 1.42 (0.92–2.18) 1.32 (0.85–2.05)
Analyses based on a Cox proportional hazards model. Reference group: residents who have never used the investigated drug or drug class during
the study period (May 2012–March 2015); the size of each reference group is 1415—number of users
aHR adjusted hazard ratio, ATC anatomical therapeutic chemical, CI confidence interval, HR hazard ratio
a See the main text for the class indicated by each ATC code
b Number of residents who fell within 60 days of their inclusion date
c Adjusted for age, sex, polypharmacy, type of care and the use of other drugs from ATC classes N05A, N05B, N05C, N06A or N06D
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(1.99) could be influenced by the patient group rather than
by the medicine. Depression is also known to increase the
risk of falls [22], and antidepressants have the potential to
impair gait, balance, and blood pressure regulation. How-
ever, the association between antidepressants and falls is
unclear [7]. The most commonly prescribed antidepressant
class in frail older adults is selective serotonin reuptake
inhibitors (SSRIs) because they lack the side effects of
traditional tricyclic antidepressants; however, this and
other studies [22, 23] have found SSRIs to be associated
with an increased risk of falling. Although a recent meta-
analysis found that many observational studies indicated an
association between SSRI use and falls, it also found that
the evidence for SSRIs causing impairments in postural
control in experimental studies such as RCTs was incon-
clusive [24, 25]. The STOPP criteria [9] recommend
amitriptyline not be used as an antidepressant because it is
associated with fall incidents. Therefore, the reason we did
not find an association between fall risk and the use of
amitriptylinemight be that it is prescribed in lower dosages
for neuropathic pain and not as an antidepressant. We
expect that confounding by indication also holds for the
risk associated with melatonin. Physicians might be
inclined to prescribe melatonin instead of hypnotic drugs
such as temazepam to patients with an increased baseline
fall risk, since melatonin is considered to have fewer side
effects. However, it has been associated with an increased
risk of fractures [26].
As expected, given the pharmacological properties, we
did not find an increased risk of falls with anti-dementia
drugs. These drugs are prescribed to prevent cognitive
decline, for aggression in moderate to severe Alzheimer’s
disease (memantine) and for psychosis in Lewy Body
dementia (cholinesterase inhibitors) [27]. The latter group
has an increased baseline risk of falls [28]. Evidently, the
potential risk of bias due to confounding by indication is
not large enough to lead to a positive association with falls.
Research indicates that differences exist within this drug
class [29]; however, we chose not to split the anti-dementia
drug group further because it was already small, and sep-
arate groups would have been too small for a regression
analysis.
Also relevant is that we did not account for dosage in
this study. However, other research suggests that the risk of
falls rises as the dose of antipsychotics, anxiolytics, hyp-
notics or sedatives, and antidepressants increases and with
the combined use of these drugs [30]. In our analysis, we
adjusted for polypharmacy but did not adjust specifically
for other drugs associated with an increased risk of falling.
Additionally, the records of the fall incidents were
dependent on nurses reporting the falls. Studies have
indicated that falls that did not result in injuries were more
often unreported than those that did [31]. This probably
does not affect the relative risks of falling but might result
in less accurate associations and larger confidence inter-
vals. This type of information bias is likely to be non-
differential (i.e. the underestimation of falls is equal for
users and nonusers of all drug classes), so this would not
influence the HRs we found. Our data only included
nursing home residents living in the eastern part of the
Table 3 Association between the use of psychotropic drugs and falls among somatic and psychogeriatric nursing home residents










Antipsychotics N05A 114 (11) 353 (27) 1.20 (0.59–2.46) 480 (99) 468 (62) 1.54 (1.11–2.13)
Typical
antipsychotics
71 (5) 396 (31) 0.79 (0.31–2.06) 341 (78) 607 (95) 1.49 (1.10–2.02)
Atypical
antipsychotics
60 (7) 407 (32) 1.65 (0.72–3.78) 221 (53) 727 (109) 1.73 (1.24–2.42)
Anxiolytics N05B 108 (13) 359 (26) 1.67 (0.83–3.36) 330 (72) 618 (95) 1.33 (0.97–1.83)
Hypnotics and
sedatives
N05C 221 (19) 246 (16) 1.40 (0.71–2.80) 443 (92) 505 (66) 1.60 (1.16–2.21)
Antidepressants N06A 163 (19) 304 (27) 1.51 (0.81–2.80) 339 (70) 609 (99) 1.40 (0.99–1.98)
Anti-Dementia
drugs
N06D 13 (2) 454 (40) 2.2 (0.51–9.73) 97 (21) 851 (150) 1.25 (0.79–2.00)
Analyses based on Cox proportional hazards model. Reference group: residents who have never used the investigated drug or drug class during
the study period (May 2012–March 2015)
a Number of residents who fell who within 60 days after their analysis inclusion date
b Adjusted for age, sex, polypharmacy, type of care and the use of other drugs from ATC classes N05A, N05B, N05C, N06A or N06D (see the
main text for the class indicated by each ATC code)
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Netherlands. Patient characteristics and the numbers
receiving psychotropic drugs were comparable to other
studies from the Netherlands [32]. Therefore, we believe
our results are representative for the Netherlands.
While our results are in line with those of others in terms
of the different drug classes, we cannot know whether the
drug classes studied in the literature comprise the same
drugs we studied. For example, while temazepam and
midazolam were the most frequently prescribed drugs, they
might not have been used as often in other studies per-
formed at another time or in another country [33, 34]. The
personal or guideline-based treatment preferences of
physicians may change over time, and new drugs may
become available on the market [35, 36]. Given the dif-
ferential prescription rates of individual drugs, a fair
comparison between the studies was difficult. This
demonstrates the flaws inherent in studying whole drug
classes and highlights the necessity of focusing on indi-
vidual drugs. In this retrospective study, we were only able
to adjust for a limited set of covariates (age, sex,
polypharmacy, and the use of other psychotropic drugs).
We were unable to adjust for comorbidity, functioning and
mobility or rule out indication or prescription bias.
This study also has strengths that must be highlighted.
The Cox model accounted for the type of care residents
received (psychogeriatric or somatic) and the other possi-
ble confounders, such as age, sex, polypharmacy and the
use of other psychotropic drugs. Furthermore, two of the
three meta-analyses included studies from different health
contexts, such as hospitals and nursing homes. The
heterogeneity of these groups might have influenced results
and increased variation. However, our results come from a
more homogenous group [37]. Whereas somatic residents
are usually characterized by serious physiological chronic
disorders, psychogeriatric residents are characterized by
serious mental or psychiatric disorders such as dementia.
Consequently, comorbidities and functional status differ
between these groups, and higher fall rates among psycho-
geriatric patients can also be attributed to the frequency of
cognitive problems, behavioral problems and additional
morbidity within this group. Therefore, we analyzed the
two groups separately and expect less confounding.
Furthermore, this study included data for 1415 residents,
with a combined 698,567 patient-days. The large amount
of available data enabled us to analyze not only drug
classes, such as antipsychotics, but also subclasses, such as
typical and atypical antipsychotics and the most commonly
used individual drugs.
Our study adds to the evidence regarding associations
between psychotropic drugs and falls. Several drugs, such as
haloperidol, quetiapine, temazepam, zolpidem and mela-
tonin, seem to increase the risk of falls. However, these
exploratory results should be further tested in a prospective
study focussing on each of these individual drugs while also
considering that fall incidents are multifactorial. Therefore,
further study should also account for all potential con-
founders such as medical conditions (comorbidities,
dementia severity, neuropsychiatric symptoms), mobility,
additional medications (e.g. to determine the Drug Burden
Index [38]) and indications for specific drugs.
Other commonly used antipsychotics, pipamperone and
risperidone, were not associated with falls and therefore
seem to be safe or at least prescribed safely. When we
analysed the data for somatic and psychogeriatric residents
separately, we found no clear association between psy-
chotropic drugs and falls in somatic residents. These results
suggest that assessing the risk of psychotropic drugs by
looking at the drug class alone is unjustified because the fall
risk may depend not only on the drug and dosage but also on
the severity of the disease (which influences overall risk of
fall). Further research focusing on the effects of the indi-
vidual drugs is needed to provide physicians with more data
that are applicable in practice. Current fall-prevention pro-
grammes consider entire drug classes to be a risk factor, but
our results suggest this needs to be reviewed. Additionally,
future studies should look at particular combinations of
psychotropic drugs associated with falls given that nursing
home residents often use several psychotropic drugs at once.
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